The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | C | Cardiovascular system | |
2 | C03 | Diuretics | |
3 | C03A | Low-ceiling diuretics, thiazides | |
4 | C03AA | Thiazides, plain |
Code | Title | |
---|---|---|
C03AA01 | Bendroflumethiazide | |
C03AA02 | Hydroflumethiazide | |
C03AA03 | Hydrochlorothiazide | |
C03AA04 | Chlorothiazide | |
C03AA05 | Polythiazide | |
C03AA06 | Trichlormethiazide | |
C03AA07 | Cyclopenthiazide | |
C03AA08 | Methyclothiazide | |
C03AA09 | Cyclothiazide | |
C03AA13 | Mebutizide |
Active Ingredient | Description | |
---|---|---|
Bendroflumethiazide |
Bendroflumethiazide inhibits the renal tubular absorption of salt and water by its action at the beginning of the distal convoluted tubule. Sodium and chloride ions are excreted in equivalent proportions. |
|
Chlorothiazide |
Chlorothiazide is a diuretic and antihypertensive. Chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. |
|
Cyclopenthiazide |
|
|
Hydrochlorothiazide |
Hydrochlorothiazide is a diuretic with antihypertensive properties. It acts by inhibiting the renal tubular re-absorption of sodium and chloride ions, which are excreted with an accompanying volume of water. Potassium excretion is also promoted. |
|
Hydroflumethiazide |
Hydroflumethiazide is a benzothiadiazine with diuretic and antihypertensive action. |
|
Methyclothiazide |
|
|
Trichlormethiazide |
|
Title | Information Source | Document Type | |
---|---|---|---|
DIDRALIN Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
RIDAQ 12.5 mg Tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
RIDAQ 25 mg / 50 mg Tablet | Health Products Regulatory Authority (ZA) | MPI, Generic |